GIPR expression in gastric and duodenal neuroendocrine tumors

Journal of Surgical Research

Volumn 190, Issue 2, 2014, Pages 587-593

  Sherman, Scott K ^a   Maxwell, Jessica E ^a   Carr, Jennifer C ^a   Wang, Donghong ^a   O'Dorisio, M Sue ^b   O'Dorisio, Thomas M ^b   Howe, James R ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Duodenal; Gastric; Gastric inhibitory polypeptide receptor; Gene expression; GIPR; Neuroendocrine tumors; Octreotide; Pancreatic; Small bowel; Somatostatin receptor

Indexed keywords

ADENOSINE A1 RECEPTOR; BETA ADRENERGIC RECEPTOR; BOMBESIN LIKE RECEPTOR 3; CHROMOGRANIN A; DOPAMINE 1 RECEPTOR; G PROTEIN COUPLED RECEPTOR 113; G PROTEIN COUPLED RECEPTOR 98; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUTAMATE RECEPTOR METABOTROPIC 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HORMONE RECEPTOR; OPIOID RECEPTOR KAPPA 1; OXYTOCIN RECEPTOR; PANCREASTATIN; POLYMERASE (RNA) II POLYPEPTIDE A; SECRETIN RECEPTOR; SEROTONIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DUODENAL NEUROENDOCRINE TUMOR; DUODENUM TUMOR; GASTRIC NEUROENDOCRINE TUMOR; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STOMACH TUMOR; TUMOR VOLUME;

DUODENAL; GASTRIC; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GENE EXPRESSION; GIPR; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC; SMALL BOWEL; SOMATOSTATIN RECEPTOR;

AGED; DUODENAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEUROENDOCRINE TUMORS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, SOMATOSTATIN; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904259606     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2014.01.044     Document Type: Article

References (37)

1. J.C. Yao, M. Hassan, and A. Phan et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 2008 3063
2. R.W. Randle, S. Ahmed, and N.A. Newman et al. Clinical Outcomes for neuroendocrine tumors of the duodenum and ampulla of Vater: a population-based study J Gastrointest Surg 2013
3. D. O'Toole, G. Delle Fave, and R.T. Jensen Gastric and duodenal neuroendocrine tumours Best Pract Res Clin Gastroenterol 26 2012 719
4. G. Delle Fave, D.J. Kwekkeboom, and E. Van Cutsem et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms Neuroendocrinology 95 2012 74
5. L.J. Hofland, and S.W. Lamberts Somatostatin receptor subtype expression in human tumors Ann Oncol 2 12 Suppl 2001 S31
6. I.M. Modlin, K. Oberg, and D.C. Chung et al. Gastroenteropancreatic neuroendocrine tumours Lancet Oncol 9 2008 61
7. A. Rinke, H.H. Muller, and C. Schade-Brittinger et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656
8. E.P. Krenning, D.J. Kwekkeboom, and W.H. Bakker et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 1993 716
9. D.J. Kwekkeboom, B.L. Kam, and M. van Essen et al. Somatostatin-receptor- based imaging and therapy of gastroenteropancreatic neuroendocrine tumors Endocr Relat Cancer 17 2010 R53
10. F.S. Dahdaleh, A. Lorenzen, and M. Rajput et al. The value of preoperative imaging in small bowel neuroendocrine tumors Ann Surg Oncol 20 2013 1912
11. J.J. Zaknun, L. Bodei, and J. Mueller-Brand et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours Eur J Nucl Med Mol Imaging 40 2013 800
12. P. Jais, B. Terris, and P. Ruszniewski et al. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours Eur J Clin Invest 27 1997 639
13. L.J. Hofland, and S.W. Lamberts The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev 24 2003 28
14. S.K. Sherman, and J.R. Howe Translational research in endocrine surgery Surg Oncol Clin N Am 22 2013 857
15. J.C. Carr, E.A. Boese, and P.M. Spanheimer et al. Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling Surgery 152 2012 998
16. J.C. Carr, S.K. Sherman, and D. Wang et al. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors Ann Surg Oncol 3 20 Suppl 2013 739
17. S.K. Sherman, J.C. Carr, and D. Wang et al. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors Surgery 154 2013 1206
18. F.S. Dahdaleh, D. Calva-Cerqueira, and J.C. Carr et al. Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution Ann Surg Oncol 19 2012 966
19. Y. Hochberg, and Y. Benjamini More powerful procedures for multiple significance testing Stat Med 9 1990 811
20. S. Faiss, U.F. Pape, and M. Bohmig et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 2003 2689
21. E.M. Wolin, K. Hu, and G. Hughes et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study Cancer Chemother Pharmacol 72 2013 387
22. M.E. Pavel, J.D. Hainsworth, and E. Baudin et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005
23. M. Pavel, E. Baudin, and A. Couvelard et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary Neuroendocrinology 95 2012 157
24. M. Korner, B. Waser, and A. Schonbrunn et al. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting Am J Surg Pathol 36 2012 242
25. F. Sclafani, C. Carnaghi, and L. Di Tommaso et al. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors Tumori 97 2011 620
26. G. Mizutani, Y. Nakanishi, and N. Watanabe et al. Expression of somatostatin receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using Real-time RT-PCR method and immunohistochemistry Acta Histochem Cytochem 45 2012 167
27. D. O'Toole, A. Saveanu, and A. Couvelard et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies Eur J Endocrinol 155 2006 849
28. J.C. Reubi, and B. Waser Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting Eur J Nucl Med Mol Imaging 30 2003 781
29. N. Irwin, and P.R. Flatt Therapeutic potential for GIP receptor agonists and antagonists Best Pract Res Clin Endocrinol Metab 23 2009 499
30. D. Prabakaran, B. Wang, and J.D. Feuerstein et al. Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells Regul Pept 163 2010 74
31. B. Waser, R. Rehmann, and C. Sanchez et al. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors J Clin Endocrinol Metab 97 2012 482
32. B. Waser, K. Beetschen, and N.S. Pellegata et al. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy Neuroendocrinology 94 2011 291
33. A. Lacroix, E. Bolte, and J. Tremblay et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion - a new cause of Cushing's syndrome N Engl J Med 327 1992 974
34. J.C. Reubi Old and new peptide receptor targets in cancer: future directions Recent Results Cancer Res 194 2013 567
35. B.D. Kerr, N. Irwin, and P.R. Flatt et al. Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance Peptides 30 2009 219
36. S.K. Sherman, J.C. Carr, and D. Wang et al. Gene expression in neuroendocrine tumor liver metastases accurately distinguishes between pancreas and small bowel primary tumors J Am Coll Surg 217 2013 S129
37. S.C. Wang, J.R. Parekh, and M.B. Zuraek et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases Arch Surg 145 2010 276